Eunice L Kwak

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. pmc Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
    Eunice L Kwak
    Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    N Engl J Med 363:1693-703. 2010
  2. pmc The role of irreversible HER family inhibition in the treatment of patients with non-small cell lung cancer
    Eunice Kwak
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    Oncologist 16:1498-507. 2011
  3. ncbi request reprint Hereditary colorectal cancer syndromes: an overview
    Eunice L Kwak
    Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    Clin Colorectal Cancer 6:340-4. 2007
  4. ncbi request reprint Targeted agents: the rules of combination
    Eunice L Kwak
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    Clin Cancer Res 13:5232-7. 2007
  5. pmc A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer
    Jason E Faris
    Department of Medical Oncology, Massachusetts General Hospital Cancer Center, POB 221, Boston, MA 02114, USA
    Invest New Drugs 30:1614-20. 2012
  6. doi request reprint Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer
    Nils D Arvold
    Harvard Radiation Oncology Program, Boston, Massachusetts, USA
    Cancer 118:3026-35. 2012
  7. pmc Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
    Alice T Shaw
    Massachusetts General Hospital Cancer Center, Boston, MA, USA
    Lancet Oncol 12:1004-12. 2011
  8. pmc FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience
    Jason E Faris
    Department of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Oncologist 18:543-8. 2013
  9. pmc Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK
    Alice T Shaw
    Department of Pathology, Massachusetts General Hospital, Warren 501c, 55 Fruit St, Boston, MA 02114, USA
    J Clin Oncol 27:4247-53. 2009
  10. pmc Preoperative cetuximab, irinotecan, cisplatin, and radiation therapy for patients with locally advanced esophageal cancer
    Michael S Lee
    Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02215, USA
    Oncologist 18:281-7. 2013

Detail Information

Publications32

  1. pmc Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
    Eunice L Kwak
    Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    N Engl J Med 363:1693-703. 2010
    ..We explored the therapeutic efficacy of inhibiting ALK in such tumors in an early-phase clinical trial of crizotinib (PF-02341066), an orally available small-molecule inhibitor of the ALK tyrosine kinase...
  2. pmc The role of irreversible HER family inhibition in the treatment of patients with non-small cell lung cancer
    Eunice Kwak
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    Oncologist 16:1498-507. 2011
    ..Results of large, randomized trials of these agents may help to determine their potential for the treatment of NSCLC...
  3. ncbi request reprint Hereditary colorectal cancer syndromes: an overview
    Eunice L Kwak
    Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    Clin Colorectal Cancer 6:340-4. 2007
    ....
  4. ncbi request reprint Targeted agents: the rules of combination
    Eunice L Kwak
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    Clin Cancer Res 13:5232-7. 2007
    ..An overview of the MTAs that have emerged as Food and Drug Administration-approved drugs is presented, along with a framework for the consideration of how MTAs can best be combined to maximize therapeutic effect...
  5. pmc A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer
    Jason E Faris
    Department of Medical Oncology, Massachusetts General Hospital Cancer Center, POB 221, Boston, MA 02114, USA
    Invest New Drugs 30:1614-20. 2012
    ..MKC-1 is an orally available cell cycle inhibitor with downstream targets that include tubulin and the importin-β family. We conducted an open-label Phase II study with MKC-1 in patients with advanced pancreatic cancer...
  6. doi request reprint Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer
    Nils D Arvold
    Harvard Radiation Oncology Program, Boston, Massachusetts, USA
    Cancer 118:3026-35. 2012
    ..Neoadjuvant chemotherapy before chemoradiation therapy (CRT) may improve outcomes for patients with locally advanced pancreatic cancer, but optimal management remains controversial, and prior reports have limited follow-up...
  7. pmc Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
    Alice T Shaw
    Massachusetts General Hospital Cancer Center, Boston, MA, USA
    Lancet Oncol 12:1004-12. 2011
    ....
  8. pmc FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience
    Jason E Faris
    Department of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Oncologist 18:543-8. 2013
    ..However, the recurrences following R0 resection in three of five patients and the toxicities observed with the use of this regimen raise important questions about how to best treat patients with LAPC...
  9. pmc Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK
    Alice T Shaw
    Department of Pathology, Massachusetts General Hospital, Warren 501c, 55 Fruit St, Boston, MA 02114, USA
    J Clin Oncol 27:4247-53. 2009
    ..To aid in identification and treatment of these patients, we examined the clinical characteristics and treatment outcomes of patients who had NSCLC with and without EML4-ALK...
  10. pmc Preoperative cetuximab, irinotecan, cisplatin, and radiation therapy for patients with locally advanced esophageal cancer
    Michael S Lee
    Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02215, USA
    Oncologist 18:281-7. 2013
    ..To determine the efficacy and toxicity of weekly neoadjuvant cetuximab combined with irinotecan, cisplatin, and radiation therapy in patients with locally advanced esophageal or gastroesophageal junction cancer...
  11. pmc Multicenter phase II study of tivozanib (AV-951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancer
    Brian M Wolpin
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Oncologist 18:377-8. 2013
    ..We evaluated tolerability and efficacy of tivozanib (an oral VEGF receptor-1, -2, -3 inhibitor) plus everolimus (an oral mammalian target of rapamycin inhibitor)...
  12. doi request reprint Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection?
    Ioannis T Konstantinidis
    Department of Surgery, Massachusetts General Hospital, Boston, MA 02114, USA
    Ann Surg 257:731-6. 2013
    ..Our aim was to compare the survival of patients undergoing an R1 resection with those having LA tumors and to explore the prognostic significance of a 1-mm surgical margin...
  13. pmc Phase 1/2 study of everolimus in advanced hepatocellular carcinoma
    Andrew X Zhu
    Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA
    Cancer 117:5094-102. 2011
    ..The phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway plays a critical role in the pathogenesis of hepatocellular carcinoma (HCC). We performed a single-arm, phase 1/2 study of everolimus in patients with advanced HCC...
  14. doi request reprint Pancreatic neuroendocrine tumors with involved surgical margins: prognostic factors and the role of adjuvant radiotherapy
    Nils D Arvold
    Harvard Radiation Oncology Program, Harvard Medical School, Boston, MA, USA
    Int J Radiat Oncol Biol Phys 83:e337-43. 2012
    ..The role of adjuvant radiotherapy (RT) in these patients has not been characterized...
  15. pmc Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab
    Raymond C Wadlow
    Massachusetts General Hospital, Boston, Massachusetts, USA
    Oncologist 17:14. 2012
    ..We performed a single-arm phase II trial of panitumumab in patients with KRAS wild-type metastatic colorectal cancer that had progressed on prior cetuximab...
  16. pmc ROS1 rearrangements define a unique molecular class of lung cancers
    Kristin Bergethon
    Massachusetts General Hospital, Boston, MA 02114 2696, USA
    J Clin Oncol 30:863-70. 2012
    ..Because little is known about these tumors, we examined the clinical characteristics and treatment outcomes of patients with NSCLC with ROS1 rearrangement...
  17. doi request reprint Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study
    Andrew X Zhu
    Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA
    Lancet Oncol 11:48-54. 2010
    ....
  18. doi request reprint Mutational and clinical predictors of pathologic complete response in the treatment of locally advanced rectal cancer
    Andrea L Russo
    Harvard Radiation Oncology Program, Boston, MA, USA
    J Gastrointest Cancer 45:34-9. 2014
    ..Mutations in critical cancer genes may contribute to lack of pCR. We retrospectively evaluated our institutional experience to determine potential mutational and clinical predictors of pCR in patients treated with CRT...
  19. doi request reprint Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy
    Lisa A Kachnic
    Department of Radiation Oncology, Boston Medical Center, Boston, MA 02118, USA
    Int J Radiat Oncol Biol Phys 82:153-8. 2012
    ..Chemoradiation for anal cancer yields effective tumor control, but is associated with significant acute toxicity. We report our multi-institutional experience using dose-painted IMRT (DP-IMRT)...
  20. doi request reprint Phase I study of preoperative short-course chemoradiation with proton beam therapy and capecitabine for resectable pancreatic ductal adenocarcinoma of the head
    Theodore S Hong
    Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Int J Radiat Oncol Biol Phys 79:151-7. 2011
    ..To evaluate the safety of 1 week of chemoradiation with proton beam therapy and capecitabine followed by early surgery...
  21. ncbi request reprint Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer
    Matthew H Kulke
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 25:4787-92. 2007
    ..We evaluated an oral regimen of capecitabine and erlotinib in patients with advanced pancreatic cancer who had experienced treatment failure with standard first-line therapy with gemcitabine...
  22. doi request reprint Targeted therapies with chemoradiation in esophageal cancer: development and future directions
    Theodore S Hong
    Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Semin Radiat Oncol 23:31-7. 2013
    ..Additionally, more recently identified targets of interest in esophagogastric cancers, including c-MET, heat shock protein 90, and Sonic hedgehog, are discussed in the context of chemoradiation...
  23. doi request reprint Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation
    Eunice L Kwak
    Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, Boston, MA 02114, USA
    Cancer 119:3043-51. 2013
    ....
  24. pmc MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib
    Jochen K Lennerz
    Massachusetts General Hospital Harvard Medical School, Boston, MA 02114, USA
    J Clin Oncol 29:4803-10. 2011
    ..We examined a GEC cohort with follow-up and reported the clinical response of four additional patients with MET-amplified tumors to the small molecule inhibitor crizotinib as part of an expanded phase I cohort study...
  25. pmc Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine
    Dora Dias-Santagata
    Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    EMBO Mol Med 2:146-58. 2010
    ..This work therefore establishes a platform for real-time targeted genotyping that can be widely adopted. We expect that efforts like this one will play an increasingly important role in cancer management...
  26. doi request reprint MDM2 promoter polymorphism and pancreatic cancer risk and prognosis
    Kofi Asomaning
    Department of Environmental Health, Harvard School of Public Health, Boston, Massachusetts, USA
    Clin Cancer Res 14:4010-5. 2008
    ..We hypothesized that the G allele is also associated with increased risk and worse outcome in pancreatic cancer...
  27. pmc Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor
    James E Butrynski
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    N Engl J Med 363:1727-33. 2010
    ..Funded by Pfizer and others; ClinicalTrials.gov number, NCT00585195.)...
  28. doi request reprint Noncurative gastrectomy for gastric adenocarcinoma should only be performed in highly selected patients
    Benjamin Schmidt
    Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    Ann Surg Oncol 20:3512-8. 2013
    ..The benefit of surgical resection in patients with incurable gastric adenocarcinoma is controversial...
  29. pmc Isolation of rare circulating tumour cells in cancer patients by microchip technology
    Sunitha Nagrath
    Surgical Services and BioMEMS Resource Center, Massachusetts General Hospital, Harvard Medical School, and Shriners Hospital for Children, Boston, Massachusetts 02114, USA
    Nature 450:1235-9. 2007
    ..It has broad implications in advancing both cancer biology research and clinical cancer management, including the detection, diagnosis and monitoring of cancer...
  30. pmc Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study
    Andrew X Zhu
    Division of Hematology Oncology, Department of Radiology, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Oncol 27:3027-35. 2009
    ..To assess the safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma (HCC) and explore biomarkers for sunitinib response...
  31. pmc Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib
    Eunice L Kwak
    Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA
    Proc Natl Acad Sci U S A 102:7665-70. 2005
    ..Our findings suggest that one of these, HKI-272, may prove highly effective in the treatment of EGFR-mutant NSCLCs, including tumors that have become resistant to gefitinib or erlotinib...
  32. pmc Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas
    Eunice L Kwak
    Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, Massachusetts 02129, USA
    Clin Cancer Res 12:4283-7. 2006
    ..Given recent reports of TKI-responsive cases of esophageal and pancreatic cancer, this study was designed to determine the prevalence of EGFR mutations in these gastrointestinal cancers...